All In Biotech

Drug Trial Radar · NCT05588843

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

187

Actual

Start

Nov 25, 2022

Primary completion

Feb 10, 2026

Study completion Dec 2, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment. At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose. In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.

Conditions

  • Colitis Ulcerative

Interventions

  • SAR443122Drug

    oral capsule

  • PlaceboDrug

    oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve clinical remission at Week 12 by modified Mayo Score (mMS)Time frame: At Week 12

Locations

106 sites in 19 countries. Site status is shown where the registry gives one.

  • Om Research - Lancaster - 15th Street West- Site Number : 8400014

    Lancaster, California

  • Agile Clinical Research Trials- Site Number : 8400024

    Atlanta, Georgia

  • Endeavor Health - Evanston Hospital- Site Number : 8400027

    Evanston, Illinois

  • BVL Research- Site Number : 8400015

    Liberty, Missouri

  • Vector Clinical Trials- Site Number : 8400004

    Las Vegas, Nevada

  • Sanmora Bespoke Clinical Research Solutions- Site Number : 8400016

    East Orange, New Jersey

  • NY Scientific- Site Number : 8400013

    Brooklyn, New York

  • Pioneer Clinical Research - New York- Site Number : 8400017

    New York, New York

  • Gastro One - Walnut Run Road- Site Number : 8400002

    Cordova, Tennessee

  • Houston Methodist Hospital- Site Number : 8400023

    Houston, Texas

  • 1960 Family Practice- Site Number : 8400019

    Houston, Texas

  • GI Alliance - Mansfield- Site Number : 8400010

    Mansfield, Texas

  • Integrity Research - Sugar Land- Site Number : 8400026

    Sugar Land, Texas

  • Richmond VA Medical Center- Site Number : 8400022

    Richmond, Virginia

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Córdoba, Argentina

  • Investigational Site Number : 0320005

    Córdoba, Argentina

  • Investigational Site Number : 0320007

    Salta, Argentina

  • Investigational Site Number : 0320006

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320001

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Investigational Site Number : 1520004

    Talcahuano, Biobio, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520005

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520006

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520007

    Viña del Mar, Valparaiso, Chile

  • Investigational Site Number : 1560001

    Guangzhou, China

  • Investigational Site Number : 1560004

    Hangzhou, China

  • Investigational Site Number : 1560003

    Hefei, China

  • Investigational Site Number : 1560006

    Nanchang, China

  • Investigational Site Number : 1560007

    Nanjing, China

  • Investigational Site Number : 1560005

    Shanghai, China

  • Investigational Site Number : 1560002

    Shenyang, China

  • Investigational Site Number : 2030007

    České Budějovice, Czechia

  • Investigational Site Number : 2030001

    Hradec Králové, Czechia

  • Investigational Site Number : 2030002

    Klatovy, Czechia

  • Investigational Site Number : 2030003

    Prague, Czechia

  • Investigational Site Number : 2500007

    Marseille, France

  • Investigational Site Number : 2500008

    Nantes, France

  • Investigational Site Number : 2500006

    Neuilly-sur-Seine, France

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.